UPDATE: Bank of America Raises PO on Puma Biotech on Ongoing Studies

In a report published Tuesday, Bank of America analyst Rachel McMinn maintained a Buy rating on Puma Biotechnology (NYSE: PBYI ), raising price target to $141.00 from $118.00 due to higher probability. According to the report, “PBYI hosted an investor call to provide an update on three ongoing clinical studies